Accelerate the development of transformative technologies and approaches to protect Americans from 21st century health security threats, including reducing the...

Program Vision

... associated with Sepsis by investing in key strategic areas.

Estimated Americans with Sepsis (this year)1

1Per CDC, over 1.7M Americans develop sepsis each year.

Our Strategy

Sepsis Program Strategy

Investing across the PARADIGM


A: Yes. The Solving Sepsis program is interested in host-based therapeutics that include demonstration of efficacy in sepsis-relevant models, with a clear regulatory plan for FDA approval.
A: Proposed approaches should include demonstration of effectiveness in sepsis relevant models (e.g. utilizing sepsis patient samples, sepsis patient data).
A: Solving Sepsis is interested in the host response to sepsis and therefore is only interested in host-based approaches when considering development of diagnostics, devices and therapeutics. BARDA has other existing programs for pathogen-targeted approaches.
A: References must be included in the technical description section of the application but can be provided as a text link to a compiled list of references. Additionally, a PMID can be provided instead of the full reference.
A: Solving Sepsis is interested in medical countermeasures that address sepsis of any etiology (i.e. bacterial, viral, other) versus approaches that are limited to sepsis induced by a subset of pathogens.
A: This may include establishment of partnerships with appropriate device fabricators/manufacturers, addressing the potential to scale, intellectual property and the means to address adoption in hospitals or other clinical settings.

For more information, please contact us at

Submit your EZ BAA Abstract

DRIVe (Division of Research, Innovation, and Ventures) was established by the Biomedical Advanced Research and Development Authority (BARDA), part of the Assistant Secretary for Preparedness and Response (ASPR), within the United States Department of Health and Human Services (HHS).